GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 89 filers reported holding GRITSTONE ONCOLOGY INC in Q2 2022. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $71 | -10.1% | 41,326 | +2.3% | 0.00% | – |
| Q2 2023 | $79 | -92.1% | 40,400 | +9802.0% | 0.00% | – |
| Q2 2022 | $1,000 | -98.9% | 408 | -98.2% | 0.00% | – |
| Q1 2022 | $95,000 | -67.9% | 23,108 | +0.3% | 0.00% | – |
| Q4 2021 | $296,000 | +18.4% | 23,036 | -0.5% | 0.00% | – |
| Q3 2021 | $250,000 | +11.1% | 23,161 | -6.1% | 0.00% | – |
| Q2 2021 | $225,000 | -2.2% | 24,654 | +1.0% | 0.00% | – |
| Q1 2021 | $230,000 | +259.4% | 24,400 | +50.6% | 0.00% | – |
| Q4 2020 | $64,000 | +48.8% | 16,200 | 0.0% | 0.00% | – |
| Q3 2020 | $43,000 | -60.2% | 16,200 | 0.0% | 0.00% | – |
| Q2 2020 | $108,000 | +14.9% | 16,200 | 0.0% | 0.00% | – |
| Q1 2020 | $94,000 | -35.2% | 16,200 | 0.0% | 0.00% | – |
| Q4 2019 | $145,000 | -34.1% | 16,200 | -36.5% | 0.00% | – |
| Q3 2019 | $220,000 | -22.5% | 25,500 | 0.0% | 0.00% | – |
| Q2 2019 | $284,000 | +435.8% | 25,500 | +537.5% | 0.00% | – |
| Q1 2019 | $53,000 | – | 4,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 3,561,150 | $6,125,178 | 3.26% |
| Redmile Group, LLC | 8,509,126 | $14,635,697 | 0.70% |
| Avidity Partners Management LP | 2,733,800 | $4,702,136 | 0.19% |
| Frazier Life Sciences Management, L.P. | 1,430,878 | $2,461,110 | 0.16% |
| Artia Global Partners LP | 95,170 | $163,692 | 0.07% |
| Worth Venture Partners, LLC | 43,772 | $75,288 | 0.04% |
| SkyOak Wealth, LLC | 60,875 | $104,705 | 0.03% |
| Point72 Asset Management, L.P. | 5,924,867 | $10,190,771 | 0.03% |
| CORNERCAP INVESTMENT COUNSEL INC | 76,811 | $132,115 | 0.02% |
| Houlihan Financial Resource Group, Ltd. | 20,000 | $38 | 0.02% |